Particle.news

Intranasal mRNA Nose Drops Restore Memory in Mice

The preclinical treatment uses lipid nanoparticles to make nasal cells produce the neurotrophic protein BDNF, offering a non‑invasive way to support neurons pending safety and delivery tests.

Overview

  • Researchers at the University of Sydney published the study on Wednesday, November 18, 2026, reporting that experimental nose drops carrying mRNA improved cognition in aged mice and protected memory in an Alzheimer’s mouse model.
  • The therapy delivers messenger RNA packaged in lipid nanoparticles derived from a BioNTech-like backbone to nasal cells, which then produce brain-derived neurotrophic factor (BDNF) for up to four days after a dose.
  • In 18-month-old mice the treatment restored performance on object recognition, working memory and spatial memory tests to levels similar to young mice and increased hippocampal markers of new neurons.
  • In the 5XFAD Alzheimer’s model, twice-weekly nasal dosing from two months prevented the expected decline by four months even though amyloid plaque levels were unchanged, suggesting function was preserved without clearing plaques.
  • The work is a proof of concept with no major short-term harms seen in the experiments, but the team says longer safety studies, delivery optimisation and tests that account for human nasal anatomy are required before human trials can proceed.